Genesis Molecular AI, the company at the forefront of AI-driven drug discovery, has announced the appointment of Sergey Edunov as Senior Vice President of Foundation Models. The move strengthens the company’s leadership in machine learning and accelerates its mission to revolutionize drug design and development. Edunov brings over two decades of experience in AI research and engineering, with a track record of building scalable, high-impact systems. Most recently, he served as Senior Director of AI Research at Meta’s generative AI organization, where he led the development of the Llama large language model series, including Llama 2 and Llama 3. Prior to that, he was a key research leader on Meta’s Fundamental AI Research (FAIR) team, driving large-scale machine translation projects. Earlier in his career, Edunov contributed to distributed infrastructure for graph algorithms at Apache Giraph, supporting Facebook’s growth and engagement initiatives. He has also held software engineering roles across multiple industries. “Sergey’s contributions to large-scale generative AI research and his ability to scale state-of-the-art models across the tech industry are invaluable as Genesis enters its next phase of growth,” said Evan Feinberg, Ph.D., founder and CEO of Genesis Molecular AI. “His expertise will be critical as we scale our GEMS platform to design and advance breakthrough medicines.” Aleksandra Faust, Ph.D., Chief AI Officer at Genesis, added, “Foundation models are transforming molecular design, and Sergey’s leadership will accelerate our ability to tackle the most complex challenges in drug discovery. His experience at Meta in delivering both research innovation and real-world impact will be instrumental in unlocking a new era of AI-driven therapeutics.” Edunov holds a Master of Science in Applied Physics and Mathematics from the Moscow Institute of Physics and Technology. He has co-authored more than 20 peer-reviewed publications, with work featured in top journals such as Nature and the Journal of Machine Learning Research, and has presented at major conferences including EMNLP. “I believe drug discovery is one of the most consequential applications of AI and offers enormous potential for patient impact,” said Edunov. “I’m thrilled to join Genesis’ exceptional team and help scale its platform to accelerate the discovery of new treatments for previously undruggable diseases.” Genesis Molecular AI, formerly known as Genesis Therapeutics, is building the world’s leading foundation models for molecular AI. Its GEMS (Genesis Exploration of Molecular Space) platform combines generative AI with physics-based modeling to design and optimize drug candidates. The platform includes the groundbreaking Pearl model, a generative diffusion system for protein structure prediction. The company has raised over $300 million from leading investors in AI, technology, and life sciences, formed strategic research partnerships with major pharmaceutical companies, and is actively advancing an internal pipeline of therapeutics for high-impact targets. Headquartered in the San Francisco Bay Area, with offices in San Diego and New York, Genesis Molecular AI is committed to transforming medicine through AI. Learn more at genesis.ml or follow the company on LinkedIn.